| abstract |
The invention is directed to methods for treating autoimmune diseases such as multiple sclerosis by orally administering a bystander antigen such as myelin basic protein or proteolipid protein in conjunction with a non-interferon polypeptide having Th2-enhancing cytokine activity in such a manner as to induce oral tolerance to the bystander antigen resulting in suppression of the autoimmune response. |